Clinical observation of gemcitabine plus carboplatin in the treatment of elder non-small call lung cancer

Objective To evaluate the curative effect and toxicity of Gemcitabine plus Carboplatin in the treatment of elder Non-Small Cell Lung Cancer. Methods sixty five elder Non-Small Cell Lung Cancer were enrolled into this study. Gemcitabine 1000 mg/m2 i. v Results It shows that CR 3.1%, PR 43.1%,NC 32.3%, PD 21.5%. The median time to progress and median survival time was 6.5 and 9.3 months, the one year survival rate was 43.1%. The main side effect include Ⅲ～Ⅳ grade leukopenia 27.7%, Ⅲ grade thombocytopenia 4.6%. Conclu-sion Gemcitabine plus Carboplatin is effective for elder Non-Small Cell Lung Cancer and well tolerated. Key words: Non-Small Cell Lung Cancer; Drug therapy; Combined therapy; Gemcitabine